Buy targets. Depending on time frame and style ( ie. starting with partial position just to be in etc) I see 2 critical factors. 1. Is the big money finished buying for now? 2. Is there a news catalyst that would cause ST price appreciation to continue?
First to watch is bid/ask spread within 5 minutes of market open and which direction it favors. Next is how much volume compared to last week each day in first half hour. This is where level 2 can be helpful in checking bid/ask sizes and which side of the trade they are stacking on.
Key price points. ST fast chart..http://stockcharts.com/h-sc/ui?s=RIGL&p=D&yr=0&mn=2&dy=0&id=p78635613776
$4.35 is bottom of price high candle body and bottom of candle tail friday close. A test of there would be very likely as we are outside the upper bb 3 consecutive days.
$4.20 the bottom of Thursdays candle and top of Wed. candle is also a real possibility if volume is weak and there happen to be profit takers. ( I can't see Institutions selling yet as they are still building positions and/or in for the long term and we are just coming off a bottom. Therefore, I will assume that selling is almost exclusively retail or mm fishing for cheap shares. Also, since retail only has 5-8% of O/S the # of sellers should be very small. Given those things, I expect any dip will be pretty short.)
$3.91 (the 10day) could be tested though I don't expect it based on the reaction Friday at $4.35.
$3.60 would be mentioned as a low target from the b/o but I think odds are low for same reasons as above.
Remember this is a fast chart with fast settings so not nearly as overbought on a normal daily as appears here. As always catalytic events trump chart TA.
Depending on Mondays trading the odds for each price point will change. Good Luck, excited to have you here.
Recent RIGL News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 08:01:11 PM
- Rigel to Present at the 2024 Cantor Global Healthcare Conference • PR Newswire (US) • 09/12/2024 12:05:00 PM
- Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML • PR Newswire (US) • 09/05/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 12:36:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 12:33:43 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/03/2024 12:30:20 PM
- Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan • PR Newswire (US) • 09/03/2024 12:00:00 PM
- Rigel to Participate in Upcoming September Investor Conferences • PR Newswire (US) • 08/29/2024 12:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/12/2024 04:15:12 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/06/2024 09:01:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:11:12 PM
- Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update • PR Newswire (US) • 08/06/2024 08:01:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/02/2024 08:53:03 PM
- Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update • PR Newswire (US) • 07/30/2024 12:05:00 PM
- Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 07/12/2024 12:05:00 PM
- Rigel Announces Reverse Stock Split • PR Newswire (US) • 06/25/2024 12:00:00 PM
- Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application • PR Newswire (US) • 06/24/2024 08:05:00 PM
- Rigel Announces Five Presentations at the EHA2024 Hybrid Congress • PR Newswire (US) • 06/14/2024 07:05:00 AM
- Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting • PR Newswire (US) • 06/03/2024 12:13:00 PM
- Rigel to Present at the Jefferies Global Healthcare Conference • PR Newswire (US) • 05/30/2024 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 11:21:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 11:21:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 11:20:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 11:20:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 11:20:11 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM